Therapeutic Areas (7)
Oncology
8 families22 subtypesSolid tumors and hematologic malignancies across all lines of therapy
Cardiology
3 families6 subtypesCardiovascular diseases including inherited cardiomyopathies, heart failure, and coronary artery disease
Autoimmune & Inflammatory
3 families7 subtypesAutoimmune and inflammatory conditions spanning rheumatology, gastroenterology, and neurology
Urology
2 families4 subtypesUrologic conditions including bladder disorders and prostate diseases
Nephrology
2 families4 subtypesKidney diseases including chronic kidney disease, glomerulonephritis, and lupus nephritis
Neurology
2 families5 subtypesNeurological disorders including neurodegenerative diseases, CNS tumors, and movement disorders
Rare Disease
2 families5 subtypesOrphan diseases including lysosomal storage disorders, neuromuscular diseases, and other rare genetic conditions
Molecular Segments (18)
| Name | Type | Description |
|---|---|---|
| EGFR | Receptor Tyrosine Kinase | Epidermal growth factor receptor mutations and amplifications driving oncogenic signaling in NSCLC and other tumors |
| BRCA1/2 | Tumor Suppressor | BRCA1 and BRCA2 germline and somatic mutations causing homologous recombination deficiency in breast, ovarian, prostate, and pancreatic cancers |
| HER2 | Receptor Tyrosine Kinase | Human epidermal growth factor receptor 2 overexpression or amplification in breast, gastric, and other cancers |
| PD-L1 | Immune Checkpoint | Programmed death-ligand 1 expression as a predictive biomarker for immune checkpoint inhibitor response |
| ALK | Receptor Tyrosine Kinase | Anaplastic lymphoma kinase rearrangements in NSCLC and anaplastic large cell lymphoma |
| KRAS G12C | Oncogene | KRAS glycine-to-cysteine substitution at codon 12, a druggable oncogenic mutation in NSCLC and colorectal cancer |
| FGFR3 | Receptor Tyrosine Kinase | Fibroblast growth factor receptor 3 alterations in urothelial carcinoma and other tumors |
| MYH7 | Structural Protein | Beta-myosin heavy chain gene mutations causing hypertrophic and dilated cardiomyopathy |
| JAK1/2 | Non-Receptor Tyrosine Kinase | Janus kinase 1 and 2 involved in cytokine signaling and targeted by JAK inhibitors in autoimmune and myeloproliferative disorders |
| TNF-alpha | Cytokine | Tumor necrosis factor alpha, a proinflammatory cytokine central to autoimmune and inflammatory disease pathogenesis |
| IL-6 | Cytokine | Interleukin-6, a pleiotropic cytokine involved in inflammation, autoimmunity, and cytokine release syndrome |
| CD20 | Cell Surface Antigen | B-lymphocyte surface antigen targeted by anti-CD20 monoclonal antibodies in lymphomas and autoimmune diseases |
| BCR-ABL | Fusion Oncogene | BCR-ABL1 fusion protein resulting from the Philadelphia chromosome translocation in CML and Ph+ ALL |
| IDH1/2 | Metabolic Enzyme | Isocitrate dehydrogenase 1 and 2 mutations producing oncometabolite 2-HG in AML, glioma, and cholangiocarcinoma |
| BRAF V600E | Oncogene | BRAF valine-to-glutamate substitution at codon 600, the most common BRAF mutation in melanoma, CRC, and NSCLC |
| RET | Receptor Tyrosine Kinase | RET proto-oncogene fusions and point mutations in thyroid cancer, NSCLC, and other solid tumors |
| NTRK | Receptor Tyrosine Kinase | Neurotrophic tyrosine receptor kinase gene fusions across multiple tumor types, eligible for tissue-agnostic therapy |
| MET | Receptor Tyrosine Kinase | MET proto-oncogene exon 14 skipping mutations and amplifications in NSCLC and other cancers |
Use Cases (14)
Trial Design
Design clinical trial protocols with evidence-backed endpoint selection, sample sizing, and stratification
Dose Optimization
Optimize dose selection using exposure-response data, PK/PD modeling, and Project Optimus principles
Biomarker Strategy
Develop biomarker-driven development strategies including validation, qualification, and CDx co-development
Regulatory Strategy
Plan regulatory pathways including IND strategy, expedited designations, and global filing strategies
Competitive Analysis
Analyze competitive landscape including pipeline tracking, differentiation assessment, and market positioning
Literature Synthesis
Synthesize published evidence from clinical trials, observational studies, and scientific publications
Endpoint Benchmarking
Benchmark clinical trial endpoints against historical trial data and regulatory acceptance patterns
Safety Assessment
Assess safety signals, benchmark adverse event profiles, and plan risk management strategies
Market Access
Develop market access strategies including pricing, reimbursement, and payer evidence requirements
Formulation Strategy
Design and justify pharmaceutical formulations with excipient selection and dosage form optimization
Manufacturing Strategy
Plan manufacturing approaches including process validation, comparability, and advanced manufacturing technologies
Post-Approval Monitoring
Track and manage post-approval commitments, REMS obligations, and ongoing regulatory requirements
Submission Preparation
Prepare regulatory submissions including IND, NDA/BLA, and supplemental applications with evidence compilation
Label Optimization
Optimize product labeling with evidence-based label claims, indication expansion analysis, and prescribing information strategy